News & Media

Press release
Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat...

Read more
Press release
Data from Medivir’s MIV-818 phase 1b study to be presented at the ESMO Congress

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled “Phase 1 study of the novel prodrug...

Read more
Press release
Medivir appoints Malene Jensen as VP Clinical Development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She...

Read more
Press release
Medivir to present at the Redeye Growth Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting Redeye Growth...

Read more
Press release
Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will present at the virtual meeting ABGSC Life Science...

Read more
Press release
Medivir announces the design of its upcoming MIV-818 combination study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced the details of its upcoming phase 1/2a combination study with the...

Read more
Press release
Positive results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients...

Read more
Press release
Resolutions at the Annual General Meeting in Medivir on 5 May 2021

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2021

January – March Financial summary for the quarter Net turnover amounted to SEK 9.9 (7.3) million. The loss before interest, tax,...

Read more
Press release
Medivir to participate at the Kempen Life Sciences Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will participate at the virtual meeting Kempen Life...

Read more
Press release
Medivir has determined the starting dose for the next part of the phase Ib study with MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient has undergone the safety follow-up to identify...

Read more
Press release
Medivir appoints Magnus Christensen as interim CEO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen, the company’s CFO,...

Read more